Publications

Publications

332 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)

Zorginstituut Nederland has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) and two ...

Report | 11-08-2021

Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)

Zorginstituut Nederland has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).

Report | 26-07-2021

GVS advice on subcutaneous buprenorphine (Buvidal®)

Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...

Report | 21-07-2021

Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)

Zorginstituut Nederland has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in the insured ...

Report | 21-07-2021

Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma

Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...

Report | 21-07-2021

Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer

Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...

Report | 21-07-2021

GVS assessment of calcifediol (Hidroferol®)

Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...

Report | 01-07-2021

Package advice niraparib (Zejula®)

Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...

Report | 24-06-2021

GVS advice SGLT-2 inhibitors

Zorginstituut Nederland has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin (Invokana®), ...

Report | 22-06-2021

GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

Report | 14-06-2021